Therachon has welcomed back Inserm Transfert Initiative for its series B round, led by Novo.

Therachon, a Switzerland-based biotechnology developer focused on rare genetic conditions, closed a $60m series B round yesterday that included Inserm Transfert Initiative, the investment arm of research institute Inserm. Pharmaceutical company Novo Holdings led the round in which Pfizer Ventures, the corporate venturing subsidiary of drug developer Pfizer and French government-owned investment bank Bpifrance also…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.